All patients
Age < 65y (younger) Age > 65y BRAF mutant BRAF wild type Gender, female Gender, male PD-L1 < 5% PD-L1 > 5% stage IIIb stage IIIc stage IV (metastatic) stage M1A stage M1B stage M1C stage M1C (with brain metastasis)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
mML - (neo)adjuvant (NA), nivolumab alone vs. ..., meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias RFS/DFSdetailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2.50 [1.26; 4.97]
2.50 [1.26 ; 4.97 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 115 NA not evaluable AE leading to death (grade 5)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.09 [0.03; 0.23]
0.09 [0.03 ; 0.23 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.09 [0.03; 0.25]
0.09 [0.03 ; 0.25 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable SAE (any grade)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.27 [0.12; 0.59]
0.27 [0.12 ; 0.59 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable SAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.29 [0.13; 0.63]
0.29 [0.13 ; 0.63 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable STRAE (any grade)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.18 [0.08; 0.41]
0.18 [0.08 ; 0.41 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable STRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.21 [0.09; 0.52]
0.21 [0.09 ; 0.52 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable TRAE (any grade)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.20 [0.04; 0.96]
0.20 [0.04 ; 0.96 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.15 [0.07; 0.34]
0.15 [0.07 ; 0.34 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable TRAE leading to death (grade 5)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable TRAE leading to discontinuation (any grade)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.09 [0.03; 0.23]
0.09 [0.03 ; 0.23 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable TRAE leading to discontinuation (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.09 [0.03; 0.25]
0.09 [0.03 ; 0.25 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Abdominal pain TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.49 [0.02; 14.80]
0.49 [0.02 ; 14.80 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.49 [0.02; 14.80]
0.49 [0.02 ; 14.80 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Alopecia TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Anaemia TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.49 [0.02; 14.80]
0.49 [0.02 ; 14.80 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Arthralgia TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 4.04 [0.18; 91.59]
4.04 [0.18 ; 91.59 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Blood and lymphatic system disorders TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Chills TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Colitis TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.16 [0.01; 3.19]
0.16 [0.01 ; 3.19 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Cough TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Diabetes TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1.98 [0.07; 60.31]
1.98 [0.07 ; 60.31 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.06; 16.10]
0.98 [0.06 ; 16.10 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Dizziness TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Dry skin TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Dysgeusia TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Dyspepsia TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Ear and labyrinth disorders TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Endocrine disorders TRAE (grade 3-4) detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.18 [0.02; 1.61]
0.18 [0.02 ; 1.61 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Eye disorders TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.49 [0.02; 14.80]
0.49 [0.02 ; 14.80 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Fatigue TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Gastritis TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.24 [0.01; 5.42]
0.24 [0.01 ; 5.42 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.11 [0.01; 0.89]
0.11 [0.01 ; 0.89 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable General disorders and administration site conditions TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.24 [0.01; 5.42]
0.24 [0.01 ; 5.42 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Headache TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.30 [0.06; 1.57]
0.30 [0.06 ; 1.57 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.13 [0.03; 0.63]
0.13 [0.03 ; 0.63 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Hypertension TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.16 [0.01; 3.19]
0.16 [0.01 ; 3.19 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1.98 [0.07; 60.31]
1.98 [0.07 ; 60.31 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Increase AST TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.33 [0.08; 1.33]
0.33 [0.08 ; 1.33 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.18 [0.05; 0.68]
0.18 [0.05 ; 0.68 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.33 [0.08; 1.33]
0.33 [0.08 ; 1.33 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.49 [0.02; 14.80]
0.49 [0.02 ; 14.80 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Metabolism and nutrition disorders TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.06; 16.10]
0.98 [0.06 ; 16.10 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Musculoskeletal and connective tissue disorders TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 6.17 [0.30; 126.14]
6.17 [0.30 ; 126.14 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Myalgia TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1.98 [0.07; 60.31]
1.98 [0.07 ; 60.31 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Myositis TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Nausea TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Nervous system disorders TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 2.00 [0.18; 22.72]
2.00 [0.18 ; 22.72 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Pancreatitis TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Paraesthesia TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.49 [0.02; 14.80]
0.49 [0.02 ; 14.80 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Pruritus TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.24 [0.01; 5.42]
0.24 [0.01 ; 5.42 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Sarcoidosis TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.32 [0.03; 3.13]
0.32 [0.03 ; 3.13 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.49 [0.02; 14.80]
0.49 [0.02 ; 14.80 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Uveitis TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Vitiligo TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Vomiting TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable Weight decreased TRAE (grade 3-4)detailed results IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] IMMUNED (NI vs N) EXPLORATORY, 2020 (REV) 1 0% 111 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-07-06 03:58 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 284,70,235
- treatments: 360,719,721,720
